Short Bowel Syndrome Market to Grow with a CAGR of 6.73% through 2030

Increasing incidence of short bowel syndrome and rising investment in research and development are factors driving the global Short Bowel Syndrome market in the forecast period 2026-2030.

According to TechSci Research report, “Short Bowel Syndrome Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Short Bowel Syndrome Market was valued at USD 854.02 Million in 2024 and is expected to reach USD 1265.38 Million by 2030 with a CAGR of 6.73% during the forecast period. Short Bowel Syndrome (SBS) is a rare and complex gastrointestinal disorder characterized by the inadequate absorption of essential nutrients due to the surgical removal of a significant portion of the small intestine. The Global Short Bowel Syndrome Market has witnessed significant growth in recent years, driven by various factors. One of the primary drivers of the Global SBS Market is the increasing incidence of Short Bowel Syndrome. This condition often results from surgical interventions for conditions such as Crohn's disease, intestinal volvulus, or trauma. The rising prevalence of these underlying diseases has contributed to a higher incidence of SBS, thus driving the demand for SBS treatments and therapies.

Pharmaceutical companies and research institutions have recognized the unmet medical needs of SBS patients, leading to increased investments in research and development. These investments have resulted in the development of new therapies and treatment options, including medications designed to improve intestinal adaptation and reduce dependency on parenteral nutrition.

Increased awareness of Short Bowel Syndrome among healthcare professionals and the general population has led to improved diagnosis rates. As healthcare providers become more familiar with SBS, they are better equipped to identify and manage the condition, thereby increasing the demand for SBS-related products and therapies.

Patients with Short Bowel Syndrome often require enteral and parenteral nutrition support to meet their nutritional needs. The expansion of these markets, along with the development of specialized nutritional products, has been a significant driver of the SBS market. Companies offering enteral and parenteral nutrition solutions have seen increased demand for their products.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Short Bowel Syndrome Market”

The Global Short Bowel Syndrome Market is segmented Drug Class, Distribution Channel, region  and company.

Based on drug class, the Glutamine segment is projected to experience the fastest growth during the forecast period. As an amino acid naturally present in the body, Glutamine plays a critical role in various metabolic processes. Recently, it has gained significant attention in treating Short Bowel Syndrome (SBS) due to its ability to support intestinal health and improve nutrient absorption. Available in both oral and intravenous forms, Glutamine is a versatile treatment option for SBS patients. Clinical studies have shown that Glutamine supplementation helps maintain intestinal mucosa integrity, reduce diarrhea, and enhance nutrient absorption, leading to better nutritional outcomes. Additionally, Glutamine is generally well-tolerated with a favorable safety profile, making it a preferred long-term treatment option compared to alternatives like parenteral nutrition (PN). Its flexibility in administration allows healthcare providers to customize treatment, optimizing therapy for individual patient needs, and driving the segment's rapid growth.

Based on region, Europe stands as the second most dominant region in terms of treatment distribution and market share. Europe’s strong healthcare infrastructure, advanced medical technologies, and comprehensive healthcare systems contribute to its significant position in the SBS market. Several factors play a role in Europe’s dominance. The region has some of the world’s most advanced healthcare systems, with countries like Germany, the United Kingdom, France, and Switzerland leading in terms of access to specialized medical care for rare diseases like SBS. These healthcare systems have established robust hospital pharmacy networks that play a central role in the diagnosis, treatment, and management of SBS. The availability of healthcare professionals trained in treating complex conditions like SBS ensures that patients receive tailored care, including therapies like parenteral nutrition and various pharmacological treatments. In addition to the healthcare infrastructure, Europe benefits from comprehensive research and development in the field of SBS treatment. Many pharmaceutical companies and biotech firms in Europe are working on innovative therapies for SBS, with several clinical trials being conducted in the region. These advancements in research contribute to a growing market for SBS treatments, as new therapies are regularly introduced to the market.

Major companies operating in Global Short Bowel Syndrome Market are:

• Wellspect Healthcare (Dentsply Sirona Company)
• Emmaus Life Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• OPKO Health, Inc.
• OxThera AB
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The future of the Global Short Bowel Syndrome Market looks promising, driven by continuous advancements in treatment options and an increasing focus on rare diseases. As new therapies, including pharmacological treatments and innovative nutritional solutions, enter the market, SBS management is expected to improve significantly. The growing prevalence of conditions leading to SBS, coupled with rising awareness and diagnosis rates, will further expand the patient pool. Additionally, the increasing adoption of advanced medical technologies and better healthcare access, particularly in regions like Europe and North America, will support market growth. Collaborative efforts between pharmaceutical companies and healthcare providers will drive research and development, enhancing the availability and efficacy of treatments, solidifying SBS's market expansion in the coming years.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class ( GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global Short Bowel Syndrome Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Short Bowel Syndrome Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com